We're going to close even or up a penny again, are
Post# of 148292
- - - - -
One other thought... I have to wonder if the FDA is massaging its sentiment about Leronlimab because a BTD for cancer might be imminent, or another catalyst that will push the molecule into the spotlight.
If Leronlimab starts getting wider and wider press, the FDA will want it to appear as though they've been team players for a long time.